Refine by
Clinical Clia Testing Equipment Supplied In Belgium
6 equipment items found
Manufactured by:UAB Brolis Sensor Technology based inVilnius, LITHUANIA
Brolis’ integrated sensor is based on swept-wavelength infrared laser absorption spectroscopy. Each molecule has a unique absorption spectrum due to its various rotational-vibrational movements. This unique absorption spectrum can be used as a fingerprint for species and concentration ...
Manufactured by:Cerhum sa based inLiège, BELGIUM
The combination of a fully biocompatible bioceramic with a patient specific shape enhanced by controlled porosity makes MyBone a unique solution for bone repair. This is made possible through the 3D-printing technology developed by ...
Manufactured by:OraSure Technologies based inBethlehem, PENNSYLVANIA (USA)
ORAQUICK RAPID HIV TESTING, ANYTIME, ANYWHERE, MADE EASY. THE ORAQUICK ADVANCE® RAPID HIV-1/2 ANTIBODY TEST DETECTS ANTIBODIES TO HIV-1 AND HIV-2 IN 20 ...
Manufactured by:OncoDNA S.A. based inGosselies, BELGIUM
Oncodeep® is a comprehensive biomarker test designed to guide treatment of advanced, metastatic solid tumors. When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn't work or when cancer comes back, OncoDEEP® can provide you with clear clinical guidance. Starting from a small sample of tumor tissue, our biomarker test is able to pinpoint ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
ConfirmMDx Addresses Prostate Biopsy Sampling Error and the False-Negative Biopsy Dilemma. “Rule-in” high-risk men who have had a previous negative biopsy result, may be harboring undetected cancer (a false-negative biopsy result), and therefore may benefit from a repeat biopsy and appropriate treatment. “Rule-out” otherwise cancer-free men from undergoing unnecessary ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1).1 The test provides binary results that, when combined with the patient’s clinical risk factors, help the ...